Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Eur Heart J
.
2019 May 14;40(19):1568.
doi: 10.1093/eurheartj/ehy743.
Authors
Jonathan P Piccini
1
,
Jyotsna Garg
1
,
Anne Hellkamp
1
,
Karen S Pieper
1
,
Manesh R Patel
1
Affiliation
1
Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
PMID:
30476238
DOI:
10.1093/eurheartj/ehy743
No abstract available
Publication types
Comment
MeSH terms
Anticoagulants
Hemorrhage
Humans
Rivaroxaban*
Warfarin*
Substances
Anticoagulants
Warfarin
Rivaroxaban